FDA Drug Recalls

Recalls / Class II

Class IID-1510-2019

Product

Temozolomide Capsules, 100 mg, packaged in a) 5-count bottle (NDC 67877-539-07), b) 14-count bottle (NDC 67877-539-14), Rx only, Manufactured by: Deva Holding A.S., 1 Merkez Mahallesi, Istanbul, Turkey 34303, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054.

Brand name
Temozolomide
Generic name
Temozolomide
Active ingredient
Temozolomide
Route
Oral
NDCs
67877-537, 67877-538, 67877-539, 67877-540, 67877-541, 67877-542
FDA application
ANDA207658
Affected lot / code info
Lot #: a) A061783, A061782, A061781, Exp 07/31/2019; A069128, Exp 05/31/2020; A071923, Exp 09/30/20; b) A061874, A061861, A061896, Exp 07/31/2019; A069326, Exp 05/31/2020; A071924, A071977, A071925, Exp 09/30/2020

Why it was recalled

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with beta lactam products.

Recalling firm

Firm
Deva Holding AS - Cerkezkoy Subesi
Manufacturer
Ascend Laboratories, LLC
Notification channel
E-Mail
Type
Voluntary: Firm initiated
Address
Organize Fatih Bulvar Fatih Bulvar 32 Cerkezkoy, N/A, Cerkezkoy, N/A N/A, Turkey

Distribution

Quantity
a) 13752 bottles; b) 15696 bottles
Distribution pattern
Nationwide in the USA.

Timeline

Recall initiated
2019-07-16
FDA classified
2019-07-23
Posted by FDA
2019-07-31
Terminated
2022-01-06
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-1510-2019. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.

Class II recall: Temozolomide · FDA Drug Recalls